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Abstract
Introduction: The oral cavity is one of the most common sites impacted by hematopoietic stem
cell transplantation (HSCT) with acute complications including mucositis, bleeding, salivary
gland dysfunction, infection, and taste alteration. These complications may result in significant
morbidity and can negatively impact outcomes such as length of stay and overall costs. As such,
oral care during HSCT for prevention and management of oral toxicities is a standard component of transplant protocols at all centers. The objective of this study was to evaluate the current oral care practices for patients during HSCT at different transplant centers within the
Eastern Mediterranean region.
Material and methods: An internet-based survey was directed to 30 transplant centers in the
Eastern Mediterranean region. The survey included five sections asking questions related to (1)
transplant center demographics; (2) current oral care protocol used at the center and type of
collaboration (if any) with a dental service; (3) use of standardized oral assessment tools and
grading systems for mucositis; (4) consultations for management of oral complications; and
(5) oral health needs at each center. Data are presented as averages and percentages.
Results: A total of 16 responses from 11 countries were collected and analyzed, indicating a
response rate of 53%. Eight centers reported that a dentist was part of the HSCT team, with
four reporting oral medicine specialists specifically being part of the team. Almost all centers
(15/16; 93%) had an affiliated dental service to facilitate pre-HSCT dental clearance with an
established dental clearance protocol at 14 centers (87%). Dental extraction was associated
with the highest concern for bleeding and the need for platelet transfusion. With respect to
infection risk, antibiotic prophylaxis was considered in the setting of low neutrophil counts with
restorative dentistry and extraction. All centers provide daily reinforcement of oral hygiene
regimen. The most frequently used mouth oral rinses included sodium bicarbonate (68%) and
chlorhexidine gluconate (62%), in addition to ice chips for dry mouth (62%). The most frequently
used mucositis assessment tools were the World Health Organization scale (7/16; 43%) and
visual analogue scale for pain (6/16; 37%). Mucositis pain was managed with lidocaine solution
(68.8%), magic mouth wash (68.8%) and/or systemic pain medications (75%).
Conclusions: Scope and implementation of oral care protocols prior to and during HSCT varied
between transplant centers. The lack of a universal protocol may contribute to gaps in oral
healthcare needs and management for this group of patients. Further dissemination of and education around available oral care guidelines is warranted.
Clinical relevance.
Considering oral care during HSCT a standard component of transplant protocols, the current
study highlights the common oral care practices for patients at centers within the Eastern
Mediterranean region.
Ó 2021 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).

Introduction

Basic oral care recommendations for hematologic
malignancy patients undergoing HSCT were published in
2015 in a position paper from the Multinational Association of Supportive Care in Cancer/International Society
of Oral Oncology (MASCC/ISOO) and the European Society
for Blood and Marrow Transplantation (EBMT) [1]. These
recommendations were developed by experts in the field
of oral medicine, hematological malignancies, and HSCT
using available literature and expert opinion to guide
healthcare providers who manage these patients. However, it is unclear up to what extent these recommendations are followed among different transplant centers and
to what extent there is variability of practice between
HSCT centers.
The objective of this study was to evaluate oral care
practices for patients during HSCT at different transplant
centers in the Eastern Mediterranean region.

The oral cavity is one of the most common sites impacted by
hematopoietic stem cell transplantation (HSCT) and associated conditioning regimens, and in the context of allogeneic
HSCT, graft versus host disease prophylaxis regimens [1].
Potential complications include oral mucositis (OM), bleeding, salivary gland dysfunction, and taste alteration [2]. Furthermore, as the mouth is colonized by the microflora,
including potentially pathogenic organisms, opportunistic
infections become a major concern [3–5]. These complications may result in significant morbidity and can negatively
impact outcomes such as length of hospital stay and overall
costs [6,7]. As such, oral care during HSCT for prevention
and management of oral toxicities is considered a standard
component of transplant protocols at all centers [8–10].
2
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fewer transplant attending physicians as part of the team.
The median number of transplant procedures performed
annually was 28 (range, 1–100), with approximately half
performed less than 30 autologous (9/16, 56.3%) and less
than 30 allogeneic (8/16, 50%) transplants annually. A dentist was included in the HSCT team at half of the centers
(n = 8), with four centers staffed specifically with Oral Medicine specialists. Overall, 14 HSCT centers would refer
patients for dental clearance prior to HSCT either to inhouse dental service (10/14; 71.4%) or affiliated dental
practice (3/14; 21.4%) or left for the patient to choose
(1/14; 7.1%). The remaining two centers did not include
pre-HSCT dental clearance as part of their protocol.

Material and methods
An internet-based survey was used to elicit information on
oral care protocols at HSCT centers as part of the Eastern
Mediterranean Blood and Marrow Transplantation (EMBMT)
group, which include 30 centers in all countries from the
eastern Mediterranean region [11]. The member countries
of EBMT include Afghanistan, Bahrain, Djibouti, Egypt, the
Islamic Republic of Iran, Iraq, Jordan, Kuwait, Lebanon,
Libya, Morocco, the Occupied Palestinian territory, Oman,
Pakistan, Qatar, Saudi Arabia, Somalia, Sudan, Syrian Arab
Republic, Tunisia, United Arab Emirates, Turkey, and
Yemen [12]. The survey was in English language and built
in SurveyMonkeyÒ (San Mateo, CA, USA). It included a total
of 32 close-ended questions divided over five sections asking
about: (1) transplant center demographics; (2) pre-HSCT
dental clearance; (3) current oral care protocol used at
the center and type of collaboration (if any) with dental service; (4) use of standardized oral assessment tools and grading systems for mucositis; and (5) consultations for
management of oral complications. For the purpose of the
survey, in-house dental service was defined as providing
dental care within the medical center and affiliated dental
service was defined as dental practice that is not based in
the medical facility yet provides dental treatment to
patients referred from medical facilities under certain
agreement and guidelines.
Prior to the distribution of the survey, validation of the
survey questions was completed through face validity by
field experts to evaluate the survey questions for the ability
to capture intended aims and check for errors such as confusing language and leading statements. The survey was
then pilot-tested through enrollment of five dentists and
five HSCT physicians, and collection of answers, comments,
and feedback. Pilot data were analyzed using principal components analysis for statistical correlations and used to
modify five questions in total [13].
The final survey was emailed to the HSCT program directors at the 30 centers within EMBMT with a request to participate in this study starting January 2019. Follow-up
emails were sent 2 and 4 weeks after the initial email to
those who did not reply. Extracted data were analyzed
and presented as averages and percentages. In addition, ttest was used for centers comparisons and statistical
significance.

Pre-HSCT dental clearance
Dental prophylaxis (plaque and calculus debridement) was
specifically part of the pre-HSCT preparation protocol at
13 centers (81.3%; Table 2). This dental procedure was more
likely to take place at centers that have a dentist as part of
the team (p = 0.46) (Table 2). During the pre-HSCT dental
clearance, centers were more inclined to prescribe antibiotic prophylaxis in the setting of neutropenia (8/16; 50%)
prior to invasive dental procedures (7/16; 43.8%), and for
patients with central venous catheters (6/16; 37.5%). This
include patients with neutropenia and absolute neutrophil
count of less than 500 cells/mL who are about to receive
dental prophylaxis (9/16; 56.3%), restorative dentistry
(10/16; 62.5%), or extractions (8/16; 50%). For bleeding
risk, five centers (31.3%) were more likely to order platelet
transfusion prior to dental prophylaxis and restorative dentistry when platelet counts fall to less than 20 K/mL. At the
same time, 10 centers (62.5%) would order platelet transfusion prior to dental extraction when platelet count falls to
less than 50 K/mL.

Current oral care protocol
Nine centers (56.3%) have implemented a written oral care
protocol and oral hygiene instructions communicated to
patients either verbally (56.3%), in writing (6.3%), or both
(37.5%) to be followed during HSCT (Table 3). As part of
the oral care protocol, eight HSCT centers (50%) would
restrict teeth brushing in the setting of thrombocytopenia
and six centers (37.5%) would not restrict in the setting of
neutropenia or thrombocytopenia. The use of dental floss
and interdental cleaning aids was prohibited at nine HSCT
centers (56.3%). The most frequently used daily mouth
rinses were sodium bicarbonate (11/16; 68%) and chlorhexidine gluconate (10/16; 62.5%). Protocols related to denture
wearing existed at only half of the centers (8/16; 50%), with
or without limitations such as in the setting of OM. Ice chips
would be used for the management of dry mouth symptoms
at more than half of the centers (10/16; 62.5%). When asked
about antifungal therapy as part of standard infectious disease prophylaxis, all centers reported using systemic fluconazole or voriconazole with variable dosages. However,
only four centers reported details on the actual regimen
used.

Ethical approval statement
A human research ethical approval was obtained through
King Abdulaziz University (Faculty of Dentistry), Jeddah,
Saudi Arabia.

Results
Transplant centers demographics
Respondents from a total of 16 HSCT centers from 11 countries participated and completed the survey with a response
rate of 53.3% (Table 1). Overall, 75% of centers had five or
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Table 1

Demographics of the HSCT Centers.

Question

Response

Frequency (%)

Country

Algeria
Egypt
Iran
Jordan
Kuwait
Lebanon
Morocco
Oman
Pakistan
Saudi Arabia
Turkey
2
3–5
6
<30
30
<30
30

1
1
1
1
1
1
1
2
2
4
1
6
6
4
9
7
8
8

How many attending transplant physicians do you have at your center?

What is the total number of autologous transplants performed at your center annually?
What is the total number of allogeneic transplants performed at your center annually?

(6.3)
(6.3)
(6.3)
(6.3)
(6.3)
(6.3)
(6.3)
(12.5)
(12.5)
(25.0)
(6.3)
(37.5)
(37.5)
(25.0)
(56.3)
(43.8)
(50.0)
(50.0)

HSCT = hematopoietic stem cell transplantation.

Table 2

Prehematopoietic Stem Cell Transplantation Dental Clearance.

Question

Response

Frequency (%)

Is there a dentist as part
of the transplant team in
your center?
Is there an Oral Medicine
specialist as part of the
transplant team in your
center?
Is there a dental service
within or affiliated with
your center?
Are HSCT patients
referred for dental
clearance prior to
transplant?
If you answered Yes for
the previous question,
where do you refer your
patients for pre-HSCT
dental clearance?
Are HSCT patients
referred for dental
prophylaxis (cleaning)
prior to transplant?

Yes
No

8 (50.0)
8 (50.0)

Yes
No

4 (25.0)
12 (75.0)

Yes
No

15 (93.8)
1 (6.3)

Yes
No

14 (87.5)
2 (12.5)

Dental service at center
Affiliated dental service, but not located at the center
Patient choice (unaffiliated dentist/dental service)

10/14 (71.4)
3/14 (21.4)
1/14 (7.1)

Yes
No

13 (81.3)
3 (18.8)

HSCT = hematopoietic stem cell transplantation.

patient develops OM, the World Health Organization
(WHO) Oral Toxicity Scale and the Oral Mucositis Assessment
Scale (OMAS) were the most routinely used instruments for
severity assessment (43.8% and 25%, respectively). Oral pain
was more likely to be assessed using the Visual Analogue

OM assessment tools and grading
When asked about OM prevention, the only specific measure
noted was palifermin (four centers, 25%) (Table 4). Once a
4
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Table 3

Oral Care during HSCT.

Question

Response

Frequency (%)

In which of any of the following
pre-HSCT dental treatment
scenarios is antibiotic prophylaxis
recommended? (you can choose
more than one)

Antibiotic prophylaxis for patients with
central venous catheter prior to an
invasive dental procedure
Antibiotic prophylaxis prior to any
invasive dental procedure
Antibiotic prophylaxis prior to any/all
dental visits pre-HSCT
Antibiotic prophylaxis in the setting of
neutropenia
We rarely prescribe antibiotics for dental
purposes
Antibiotic prophylaxis is not
recommended
>10,000
>20,000
>30,000
>40,000
>50,000
Platelet transfusions are not considered
or coordinated in the context of preHSCT dental treatment
>10,000
>20,000
>30,000
>40,000
>50,000
Platelet transfusions are not considered
or coordinated in the context of preHSCT dental treatment
>10,000
>20,000
>30,000
>40,000
>50,000
Platelet transfusions are not considered
or coordinated in the context of preHSCT dental treatment
<500
<750
>1,000
<1,000
Not routinely done

6 (37.5)

9
0
5
2
0

<500
<750
>1,000
<1,000
Not routinely done

10 (62.5)
0 (0)
3 (18.8)
2 (12.5)
1 (6.3)

<500
<750
>1,000
<1,000
Not routinely done

8
1
5
1
1

Yes
No

9 (56.3)
7 (43.8)

Please provide the platelet count
threshold at which a platelet
transfusion would be indicated
prior to: Dental prophylaxis
(anticipate gingival bleeding)

Please provide the platelet count
threshold at which a platelet
transfusion would be indicated
prior to: Restorative dentistry (no
or minimal bleeding anticipated)

Please provide the platelet count
threshold at which a platelet
transfusion would be indicated
prior to: Dental extraction(s)
(significant bleeding anticipated)

Please provide the absolute
neutrophil count threshold at
which antibiotic prophylaxis
would be indicated prior to:
Dental prophylaxis (anticipate
gingival bleeding)
Please provide the absolute
neutrophil count threshold at
which antibiotic prophylaxis
would be indicated prior to:
Restorative dentistry (no or
minimal bleeding anticipated)
Please provide the absolute
neutrophil count threshold at
which antibiotic prophylaxis
would be indicated prior to:
Dental extraction(s) (significant
bleeding anticipated)
Does your center have a
written/documented oral care
protocol?

7 (43.8)
1 (6.3)
8 (50.0)
4 (25.0)
1 (6.3)
1
5
2
1
3
4

(6.3)
(31.3)
(12.5)
(6.3)
(18.8)
(25.0)

1
5
3
0
3
4

(6.3)
(31.3)
(18.8)
(0)
(18.8)
(25.0)

1 (6.3)
1 (6.3)
2 (12.5)
1 (6.3)
10 (62.5)
1 (6.3)

(56.3)
(0)
(31.3)
(12.5)
(0)

(50.0)
(6.3)
(31.3)
(6.3)
(6.3)

(continued on next page)
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Table 3

(continued)

Question

Response

Frequency (%)

In your center, oral hygiene
instruction for the patient is
provided:
In which of the following
scenarios is traditionally tooth
brushing restricted?

Verbally
Written
Both verbally and written
Tooth brushing is never restricted
Tooth brushing is restricted with
neutropenia
Tooth brushing is restricted with
thrombocytopenia
Tooth brushing is restricted with
thrombocytopenia and neutropenia
No
Yes, recommended always without
limitations
Yes, except for pediatric patients
Only with acceptable platelet count and
no oral mucositis
Only under supervision
Only gentle flossing
Saline 0.9%
Chlorhexidine 0.12%
Dibasic sodium phosphate (CaphosolÒ)
Sodium bicarbonate 1%
Nystatin 100,000 IU
Povidone iodine 0.1%
Hexetidine (RinsidinÒ) 0.1%
Lidocaine solution 2%
Patient is allowed to use the denture at
all times without limitations
Patient is allowed to use the denture but
with limitations
Patient is allowed to use the denture
except when there is oral mucositis
No protocol available
BioteneÒ products
Dibasic sodium phosphate (CaphosolÒ)
Fluoride rinse
Ice chips
Ice cream
No specific measures are available

9
1
6
6
1

Is the use of dental floss or an
interdental cleaning aid
permitted during HSCT?

Which of the following (if any)
mouth rinses are included as part
of standard oral care regimen?
(you can choose more than one
answer as applicable)

What is the protocol for patients
with dentures during the course
of HSCT?

Which of the following are used
for dry mouth management
during HSCT? (you can choose
more than one answer as
applicable)

(56.3)
(6.3)
(37.5)
(37.5)
(6.3)

8 (50.0)
1 (6.3)
9 (56.3)
3 (18.8)
1 (6.3)
1 (6.3)
1 (6.3)
1 (6.3)
6 (37.5)
10 (62.5)
4 (25.0)
11 (68.8)
3 (18.8)
1 (6.3)
1 (6.3)
1 (6.3)
4 (25.1)
4 (25.0)
1 (6.3)
8 (50.0)
2 (12.6)
4 (25.0)
2 (12.5)
10 (62.5)
1 (6.3)
4 (25.0)

HSCT = hematopoietic stem cell transplantation.

eases) to make a joint decision on a case-by-case basis
(Table 4). Patients with dental needs during or early after
HSCT were more likely to be referred to a dental service
within the transplant center (56.3%) when the team
included a dentist (p = 0.018). Other centers indicated
referrals to either a dental office of the patient’s choice
(25%) or an affiliated dental service (18.8%).

Scale (VAS; 37.5%), followed by Numeric Rating Scale (NRS;
25%). Most centers (81.3%) assess oral health status once
daily. Patients with pain related to OM were managed with
systemic pain medication (12/16; 75%), topical lidocaine
(11/16; 68.8%), and/or magic mouthwash (11/16; 68.8%).
Of the various pain control regimens, magic mouthwash
was more likely to be prescribed by teams that included a
dentist (p = 0.28).

Discussion

Management of acute odontogenic complications

According to WHO, more than 50,000 HSCT procedures are
carried out annually worldwide [14]. This special group of
patients is typically at risk of myelosuppression as well as

If a patient were to develop acute dental pain during HSCT,
11 centers (68.8%) were likely to request a consultation with
other services (e.g., dental team in-house or infectious dis6
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Table 4

Management of Oral Mucositis and Other Oral Complications.

Question

Response

Frequency (%)

Please describe any measures
routinely utilized for oral
mucositis prevention:

Palifermin (KepivanceÒ)
Cryotherapy
Sodium bicarbonate and nystatin
Magic Mouthwash
None
Lidocaine solution 2%
Magic mouth wash
Caphosol
Systemic pain medication and patches (opioid
agents such as fentanyl transdermal patch,
methadone, and patient-controlled analgesia)
Sucralfate
Cryotherapy
Menthol and phenol containing lozenges
World Health Organization (WHO) Oral Toxicity
Scale with or without modifications
Oral Mucositis Assessment Scale (OMAS)
The European Organization for Research and
Treatment of cancer/Radiation Therapy
Oncology Group (EORTC/RTOG)
National Cancer Institute Common Toxicity
criteria Scale (NCI)
Oral Mucositis Index (OMI)
Multinational Association of Supportive Care in
Cancer (MASCC)
None
3 times daily
2 times daily
1 time daily
2–3 times weekly
Visual analogue scale (VAS)
The Miller scale” (an 11-point numeric scale)
The Whaley and Wong Faces Pain Rating Scale
Numeric Rating Scale (NRS)
Patient reported response (Yes/No)
Manage with pain medication/antibiotics until a
patient is discharged or otherwise fit for
discharge
Consultation with other services (e.g., dental
team in-house or infectious diseases) and make a
joint decision on a case-by-case basis
Dental service within your transplant center
Affiliated dental service
Patient can visit the dental practice of their
choice
Yes

4 (25.0)
3 (18.8)
1 (6.3)
1 (6.3)
7 (43.8)
11 (68.8)
11 (68.8)
2 (12.5)
12 (75.0)

Which of the following are used
for oral mucositis pain
management? (you can choose
more than one answer as
applicable)

Which of the following are
routinely used for oral mucositis
assessment/measurement?
(check all that apply)

How frequently is oral mucositis
assessed?

Which of the following pain scale
is used to measure oral mucositis
pain?

How do you manage a patient
with acute dental pain during
HSCT?

Where do you refer HSCT patients
with dental needs during or early
after HSCT (within the first
100 days)?
Is antifungal therapy included as
part of standard infectious
disease prophylaxis for HSCT
patients?
If yes, please specify the agent,
dose, and duration.

Voriconazole 200 mg (IV or orally twice a day)
Fluconazole 200 mg/d until engraftment (if
concurrent with active fungal infection then a
joint decision with infectious diseases team)
Fluconazole 400 mg orally once a day starting on
Day 3
Voriconazole 200 mg twice a day for 3–6 months

7

2
1
1
7

(12.5)
(6.3)
(6.3)
(43.8)

4 (25.0)
1 (6.3)

3 (18.8)
1 (6.3)
1 (6.3)
4 (25.1)
1 (6.3)
1 (6.3)
13 (81.3)
1 (6.3)
6 (37.5)
1 (6.3)
2 (12.5)
4 (25.0)
1 (6.3)
5 (31.3)

11 (68.8)

9 (56.3)
3 (18.8)
4 (25.0)
16 (100)

1 (6.3)
1 (6.3)

1 (6.3)
1 (6.3)
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As bleeding and infection risk must be considered in the
context of HSCT patients, we attempted to better understand the transplant centers’ views of dental procedures
for this population of patients. Antibiotic prophylaxis was
one measure reported by 50% of centers to prevent the risk
of infection. This approach was more considered prior to
invasive dental procedures (e.g., dental prophylaxis, deeper
dental restorations close to the pulp and extractions) (7/16;
43.8%) and for patients with central venous catheters (6/16;
37.5%). As of today, no clinical documentation of catheterrelated infection has been associated with dental procedures
[20]. However, numerous recommendations in the literature
endorse antibiotic prophylaxis administration, which continues to be a controversial topic. The risk of bleeding was also
raised in this survey as the platelet count threshold set by
participating centers (5 centers; 31.3%) was < 20 K/mL prior
to dental prophylaxis and restorative dentistry and < 50,000
prior to dental extraction at 10 centers (62.5%). Even with
the lack of clear guidelines, these thresholds are compared
to what has been reported in the literature as an indication
for platelet transfusion prior to invasive dental procedures
ranging between 10 and 50 K/mL [21–23].
During HSCT, patients are typically at increased risk for OM
with an international reported prevalence of OM ranging
between 58% and 80% [24]. It presents clinically as breakdown
and ulceration of the mucosal lining causing discomfort, pain,
and/or dysphagia, and difficulty in speaking [17,24,25]. Palifermin (Kepivance Ò), a human keratinocyte growth factor, is
one treatment option that has been developed for the prevention of OM and investigated extensively with mixed outcomes
[26]. Cost, systemic route of administration, and lack of sufficient supporting evidence are the major factors that preclude
the inclusion of palifermin as standard of care for HSCT
patients [27–29]. In the current study, seven centers (43.8%)
reported no specific measures implemented for OM prevention
and 4 (25%) participating centers have implemented palifermin as part of their transplant protocol.
More than half of the centers in the current study (n = 9;
56.3%) have implemented an oral care protocol with basic
oral hygiene instructions, slightly higher than what has been
reported previously [1,10,30]. Owing to increased risk of
oral bleeding and/or infection, physicians/HSCT centers
may refrain from allowing toothbrushing during the HSCT
phase in the setting of severe thrombocytopenia (8/16;
50%) and severe neutropenia as reported by a single center
(6.3%). However, six centers (37.5%) were more likely to
allow such activity with no restrictions. Even with the
MASCC/ISOO recent position paper advising for dental flossing for experienced HSCT patients with needed dexterity,
four centers (25.2%) adopted limited use and it was completely restricted at nine centers (56.3%) [1].
Mouth rinses are frequently included as part of an oral
hygiene regimen in HSCT patients for antimicrobial effects,
lubrication and mechanical washing out of food debris
[31,32]. Overall, sodium bicarbonate mouth rinse was the
most frequently used among participating centers (11/16;
68%). The second most frequently used mouthwash was
chlorohexidine gluconate, which despite not being effective
in reducing the risk of OM, has well-established antimicrobial activities (10/16; 62.5%) [10].
Acute dental pain (e.g., dental abscess, fractured
restoration), oral bleeding, and infections are potential

immunosuppression mediated by hematological disease,
cancer therapy, or both [1]. This procedure frequently
results in a series of oral complications with variable onset
(during or after HSCT) and duration affecting up to 80% of
HSCT patients [15]. One way to ensure optimum oral health
status in patients undergoing HSCT is through the implementation of an oral care protocol as part of the HSCT process
[1]. However, heterogeneity in oral care protocols may exist
among different HSCT centers, and this could contribute to
variability in outcomes.
The position paper from MASCC/ISSO has highlighted several aspects related to oral care for HSCT patients [1]. The
primary, community dentist coordination with the oral medicine specialist and transplant team may have an important
role in preparing the patient for transplant as well as management or short- and long-term oral complications. PreHSCT dental clearance and continuous follow-up after HSCT
will decrease the risk of OM, infections, and dental caries.
The position paper emphasized on the importance of multidisciplinary approach for this specific population of patients
as a key for HSCT success.
It is increasingly recognized that a multiprofessional
HSCT team is essential to improve transplant success and
enhance patients’ quality of life [16]. The presence of a
dentist as part of the transplant team is crucial to establish
and maintain the delivery of oral care protocols and manage
acute oral complications as indicated. Moreover, the presence of a supporting dental service on-site facilitates
patient management prior to, during, and after HSCT. Half
of the centers in the current study reported having a dentist
as part of the team, with half (4 centers) specifically staffed
with Oral Medicine specialists. The size of the facility and
the total number of transplant physicians may have an
impact on the decision to include Oral Medicine specialists
in the team: centers with one to four transplant consultants
were less likely to have an Oral Medicine specialist as part of
the team compared to centers with > 5 consultants, which
accounted for 75% of the participating centers (p = 0.07).
Other potential roles for Oral Medicine specialists are diagnosis and management of oral mucosal and salivary gland
diseases, which are common complications in this population of patients [1,17].
Most centers (14/16; 87.5%) have included dental
clearance prior to HSCT in their routine protocol to
reduce the risk of oral infections and complications. To
complete the needed dental procedures prior to HSCT, a
dental service affiliated or based within the transplant
facility was available at all but one center (93.8%). This
number is higher than the MASCC/ISOO report of 75%
(55/74) of participating international members in a survey
who stated that they referred patients for dental clearance, in which 25% (13/55) reported to have dental services delivered in-house [18]. The remaining 75% were
likely to be referred to community-based dentists, an
approach that has been reported to be effective with high
levels of compliance [19]. Guidance from an Oral Medicine specialist to community-based dentists who are less
familiar with HSCT patients may facilitate this process
[17,19]. Although not investigated in this survey, potential
barriers to completing pre-HSCT dental clearance include
cost/lack of dental insurance, access to care, and time
limitations [16].
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complications during HSCT, which pose a continuous challenge for the transplant team [1,33]. Once detected, clinical examination and further investigations are indicated,
which could be performed by the transplant team or via
consultation with other services in the facility to ensure a
proper diagnosis. In this survey, 11 centers (68.8%) were
more inclined to request a consultation from an in-house
dental team or infectious disease services. This finding highlights the importance of having a dentist as part of the
transplant team to ensure proper management and better
access. Potential challenges for this approach include the
cost and availability of dentists with knowledge and clinical
experience to treat patients receiving HSCT [16].
The current study has several limitations. First, even
with a response rate of 53.3%, the total starting number
of participating centers is still small. Second, the oral care
survey was completed by the transplant center director,
which may not represent possible protocol variations
between providers. In addition, dental-related questions
may have not been answered accurately. Direct contact
with individual transplant physicians may have provided different responses. Third, based on the nature of the study,
no attempt was conducted to survey each HSCT center
within the EMBMT group for more specific details on daily
practice. Center-specific differences within each region or
country may have existed. Lastly, there was potential for
response bias, which may have inaccurately inflated certain
reported oral care practices.
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